Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 7/20 | 1.00 |
| ▸ | PRKACA | P17612 | 7/20 | 1.00 |
| ▸ | GSK3A | P49840 | 7/20 | 1.00 |
| ▸ | GSK3B | P49841 | 7/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 7/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 6/20 | 1.00 |
| ▸ | KDR | P35968 | 6/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 6/20 | 1.00 |
| ▸ | LIMK1 | P53667 | 6/20 | 1.00 |
| ▸ | RPS6KA3 | P51812 | 6/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 6/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 5/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 5/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 5/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 5/20 | 1.00 |
| ▸ | FLT1 | P17948 | 4/20 | 1.00 |
| ▸ | AURKA | O14965 | 4/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 4/20 | 1.00 |
| ▸ | CLK2 | P49760 | 4/20 | 1.00 |
| ▸ | MAP4K2 | Q12851 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9230695 | 1.00 | PIM1 (1.00) | PIM1PRKACAGSK3AGSK3BCDK5 | |
| SCHEMBL28769185 | 0.86 | DAPK3 (0.76) | PIM1PRKACAGSK3AGSK3BCDK5 | |
| SCHEMBL844094 | 0.84 | AURKA (0.73) | PIM1PRKACAGSK3AGSK3BCDK5 | |
| SCHEMBL30514630 | 0.84 | AURKA (0.73) | PIM1PRKACAGSK3AGSK3BCDK5 | |
| SCHEMBL5951059 | 0.83 | CHEK1 (0.71) | PIM1PRKACAGSK3AGSK3BCDK5 | |
| SCHEMBL13977223 | 0.83 | DYRK1A (0.71) | PIM1PRKACAGSK3AGSK3BCDK5 | |
| SCHEMBL30568740 | 0.83 | CHEK1 (0.71) | PIM1PRKACAGSK3AGSK3BCDK5 | |
| SCHEMBL162420 | 0.79 | CDK8 (0.65) | PIM1PRKACAGSK3AGSK3BCDK5 | |
| SCHEMBL7621269 | 0.79 | CDK8 (0.65) | PIM1PRKACAGSK3AGSK3BCDK5 | |
| SCHEMBL30298119 | 0.79 | CHEK1 (0.65) | PIM1PRKACAGSK3AGSK3BCDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118994104-A | Compound serving as PARP-NAMPT double-target inhibitor and application thereof | 天津市医药科学研究所(天津市医药与健康研究中心) | 2024-11-22 | — | — | CN | claimed |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| CN-118994104-A | Compound serving as PARP-NAMPT double-target inhibitor and application thereof | 天津市医药科学研究所(天津市医药与健康研究中心) | 2024-11-22 | — | — | CN | disclosed |
| CN-118702627-A | CD73 small molecule inhibitor, pharmaceutical composition and application thereof | 深圳市新樾生物科技有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-116730995-B | Hydrazide compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2024032715-A1 | HYDRAZIDE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | 深圳微芯生物科技股份有限公司 | 2024-02-15 | — | — | WO | disclosed |
| CN-116730995-A | Hydrazide compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-113788827-B | Phthalazinone compound, preparation method and medical application thereof | 中国药科大学 | 2023-04-25 | — | — | CN | disclosed |
| US-20230110003-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | Valo Health, LLC | 2023-04-13 | — | — | US | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11479564-B2 | Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT) | VALO HEALTH, INC. (US) | 2022-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NNT | PIM1 3710/4885PRKACA 2619/4885GSK3A 677/4885 |
| US-20230110003-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | NAMPT, NAPRT, NNMT | PIM1 2932/4885PRKACA 902/4885GSK3A 2197/4885 |
| US-11479564-B2 | Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT) | NAMPT, NAPRT, NNMT | PIM1 2932/4885PRKACA 902/4885GSK3A 2197/4885 |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | PIM1 3712/4885PRKACA 2472/4885GSK3A 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.